
Max Healthcare Q2 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 2- Occupied bed days grew 3% YoY and 5% QoQ with average occupancy at 77%; inpatient discharges up 7% YoY.
- Network gross revenue increased 17% YoY, driven by ARPOB growth and higher occupied bed days.
- Revenue from international business grew 25% YoY and 11% QoQ; international revenue now ~9% of hospital revenue.
- Oncology specialty revenue growing faster (26%-28%) than overall business (17%), driven by higher disease burden and insurance penetration.
- Capacity to expand with 2,600 beds coming online over next 3-4 years, adding significant growth runway.
- Institutional business ARPOB up 28% YoY due to mix change rather than price hike.
- Expect continued multi-decade growth opportunity due to under-penetration of quality healthcare in India.
- EBITDA and cash flow expected to maintain robust growth trajectory with bed expansions and operational efficiencies.
See what Max Healthcare management said on margin guidance — free account, 30 seconds.
Fundraise plans
See what Max Healthcare management said on order book — free account, 30 seconds.
Capex plans
Yes- Ongoing expansions include 2,600 beds with 300 beds expected by FY24-end and approximately 819 beds in FY25 (Nanavati 329 beds, Mohali 190 beds, Gurgaon 300 beds).
- Max Shalimar Bagh brownfield expansion operational with 78% occupancy; brownfields have quick EBITDA breakeven (within quarter or two).
- Greenfield projects comprise 10% of expansion with breakeven expected within 12 months.
- Max Smart at Saket: 350 beds delayed but work to restart by Dec 2023.
- Max Vikrant at Saket and Patparganj expansions progressing with approvals underway.
- Strategic focus on fiscal discipline while deploying cash; acquisitions considered at right price but prefer built-to-suit, asset-light models over Greenfields.
- Developer of Dwarka hospital (300 beds) applied for occupancy certificate, expected commissioning Q4 2023.
- Planned capital deployment on both capacity expansion and inorganic opportunities; accumulation of cash with intent to invest soon.
Track Max Healthcare — get its next earnings analysis in your feed
How does Max Healthcare rank vs peers in Healthcare Services?
Pro featureHow does Max Healthcare rank in Healthcare Services?
Compare Max Healthcare against every Healthcare Services company (Q2 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Max Healthcare's management said in earlier quarters
Others in Healthcare Services this season
- Chandan Healthca (Q2 FY27)
Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor
- Invicta Diagnostic (Q2 FY27)
Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2
- Unihealth Hosp (Q2 FY27)
1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r
- Sangani Hospital (Q2 FY27)
1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.